IMMUNIC, INC. Files 10-Q for Period Ending March 31, 2024

Ticker: IMUX · Form: 10-Q · Filed: May 8, 2024 · CIK: 1280776

Immunic, INC. 10-Q Filing Summary
FieldDetail
CompanyImmunic, INC. (IMUX)
Form Type10-Q
Filed DateMay 8, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, IMMUNIC, Financial Report, Quarterly Filing, SEC Filing

TL;DR

<b>IMMUNIC, INC. filed its quarterly report (10-Q) for the period ending March 31, 2024.</b>

AI Summary

IMMUNIC, INC. (IMUX) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. IMMUNIC, INC. filed a 10-Q report for the period ending March 31, 2024. The company's fiscal year ends on December 31. The filing was made on May 8, 2024. The company's business and mailing address is in New York, NY. IMMUNIC, INC. was formerly known as VITAL THERAPIES INC.

Why It Matters

For investors and stakeholders tracking IMMUNIC, INC., this filing contains several important signals. This 10-Q filing provides an update on IMMUNIC, INC.'s financial performance and operational status for the first quarter of 2024. Understanding the details within this report is crucial for investors to assess the company's current financial health, strategic direction, and potential risks.

Risk Assessment

Risk Level: medium — IMMUNIC, INC. shows moderate risk based on this filing. The company's financial statements and risk factors, typically detailed in a 10-Q, will reveal its current cash position, debt levels, and any emerging operational or market challenges that could impact its valuation.

Analyst Insight

Review the "Financial Statements" and "Risk Factors" sections of the 10-Q to understand IMMUNIC, INC.'s financial health and potential headwinds.

Key Numbers

Key Players & Entities

FAQ

When did IMMUNIC, INC. file this 10-Q?

IMMUNIC, INC. filed this Quarterly Report (10-Q) with the SEC on May 8, 2024.

What is a 10-Q filing?

A 10-Q is a quarterly financial report with unaudited financials, management discussion, and interim business updates. This particular 10-Q was filed by IMMUNIC, INC. (IMUX).

Where can I read the original 10-Q filing from IMMUNIC, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by IMMUNIC, INC..

What are the key takeaways from IMMUNIC, INC.'s 10-Q?

IMMUNIC, INC. filed this 10-Q on May 8, 2024. Key takeaways: IMMUNIC, INC. filed a 10-Q report for the period ending March 31, 2024.. The company's fiscal year ends on December 31.. The filing was made on May 8, 2024..

Is IMMUNIC, INC. a risky investment based on this filing?

Based on this 10-Q, IMMUNIC, INC. presents a moderate-risk profile. The company's financial statements and risk factors, typically detailed in a 10-Q, will reveal its current cash position, debt levels, and any emerging operational or market challenges that could impact its valuation.

What should investors do after reading IMMUNIC, INC.'s 10-Q?

Review the "Financial Statements" and "Risk Factors" sections of the 10-Q to understand IMMUNIC, INC.'s financial health and potential headwinds. The overall sentiment from this filing is neutral.

How does IMMUNIC, INC. compare to its industry peers?

IMMUNIC, INC. operates in the pharmaceutical preparations industry, focusing on developing novel therapies.

Are there regulatory concerns for IMMUNIC, INC.?

As a publicly traded company, IMMUNIC, INC. is subject to SEC regulations, including the requirement to file quarterly reports (10-Q) to disclose financial and operational information.

Industry Context

IMMUNIC, INC. operates in the pharmaceutical preparations industry, focusing on developing novel therapies.

Regulatory Implications

As a publicly traded company, IMMUNIC, INC. is subject to SEC regulations, including the requirement to file quarterly reports (10-Q) to disclose financial and operational information.

What Investors Should Do

  1. Analyze the financial statements for revenue, expenses, and cash flow.
  2. Review the Management's Discussion and Analysis for insights into business strategy and outlook.
  3. Examine the Risk Factors section for potential challenges and uncertainties.

Key Dates

Year-Over-Year Comparison

This is the 10-Q filing for the period ending March 31, 2024, providing an update from previous filings.

Filing Stats: 4,477 words · 18 min read · ~15 pages · Grade level 14.2 · Accepted 2024-05-08 07:20:20

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Condensed Consolidated Financial Statements (Unaudited)

Item 1. Condensed Consolidated Financial Statements (Unaudited) Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Loss 5 Condensed Consolidated Statements of Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 7 Notes to Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 22

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 34

Controls and Procedures

Item 4. Controls and Procedures 34

- OTHER INFORMATION

PART II - OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 35

Risk Factors

Item 1A. Risk Factors 35

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 35

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 35

Other Information

Item 5. Other Information 35

Exhibits

Item 6. Exhibits 35 2 IMMUNIC, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) March 31, 2024 December 31, 2023 (Unaudited) Assets Current assets: Cash and cash equivalents $ 97,312 $ 46,674 Other current assets and prepaid expenses 5,303 5,860 Total current assets 102,615 52,534 Property and equipment, net 442 466 Right-of-use assets, net 1,098 1,299 Total assets $ 104,155 $ 54,299 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 6,767 $ 5,099 Accrued expenses 12,419 18,664 Other current liabilities 960 966 Total current liabilities 20,146 24,729 Long-term liabilities Operating lease liabilities 433 639 Total long-term liabilities 433 639 Total liabilities 20,579 25,368 Commitments and contingencies (Note 4) Stockholders' equity: Preferred stock, $ 0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of March 31, 2024 and December 31, 2023 — — Common stock, $ 0.0001 par value; 500,000,000 and 130,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively, and 90,079,016 and 45,177,730 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 8 4 Additional paid-in capital 519,757 436,060 Accumulated other comprehensive income 4,287 3,759 Accumulated deficit ( 440,476 ) ( 410,892 ) Total stockholders' equity 83,576 28,931 Total liabilities and stockholders' equity $ 104,155 $ 54,299 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 IMMUNIC, INC. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited) Three Months Ended March 31, 2024 2023 Operating expenses: Research and development $ 18,736 $ 22,963 General and administrative 5,145 4,288 Total operating expenses 23,881 27,251 Loss from operations ( 23,881 ) ( 27,251 ) Other income (expense):

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing